New Rochelle, NY, July 1, 2014Christof von Kalle, MD, PhD (National Center for Cancer Research, Heidelberg, Germany) began his medical and research career with a focus on oncology and virology. He subsequently devoted much of his efforts to studying the use of viral vectors to deliver therapeutic genes into host cells and understanding the mechanisms of insertional mutagenesis. In recognition of his leadership and accomplishments, Dr. von Kalle has received a Pioneer Award from Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Human Gene Therapy is commemorating its 25th anniversary by bestowing this honor on the leading 12 Pioneers in the field of cell and gene therapy selected by a blue ribbon panel* and publishing a Pioneer Perspective by each of the award recipients. The Perspective by Dr. von Kalle is available on the Human Gene Therapy website.
In "Vector Integration and Tumorigenesis," Dr. von Kalle recalls his early experiences working with retroviral vectors and the growing body of knowledge that was developing about their ability to cause mutations at the sites where they integrated into the host cell genome. He discusses the teamwork, intensive research, and technology advances that led to a growing understanding of the link between vector insertion, mutation, and malignant transformation of cells. Tracing the progress of the field forward to the present and looking to the future, Dr. von Kalle comments on the revolutionary impact that next generation sequencing technologies, molecular tools and techniques, and omics studies are having on gene therapy.
"The level of sophistication that Dr. von Kalle has brought to the analysis of vector integration is truly remarkable," says James M. Wilson, MD, PhD, Editor-in-Chief of H
|Contact: Kathryn Ruehle|
Mary Ann Liebert, Inc./Genetic Engineering News